Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis
Top Cited Papers
- 27 April 2017
- Vol. 72 (10), 876-883
- https://doi.org/10.1136/thoraxjnl-2016-209719
Abstract
Rationale We hypothesised that patients with acute respiratory distress syndrome (ARDS) can be clustered based on concentrations of plasma biomarkers and that the thereby identified biological phenotypes are associated with mortality. Methods Consecutive patients with ARDS were included in this prospective observational cohort study. Cluster analysis of 20 biomarkers of inflammation, coagulation and endothelial activation provided the phenotypes in a training cohort, not taking any outcome data into account. Logistic regression with backward selection was used to select the most predictive biomarkers, and these predicted phenotypes were validated in a separate cohort. Multivariable logistic regression was used to quantify the independent association with mortality. Results Two phenotypes were identified in 454 patients, which we named ‘uninflamed’ (N=218) and ‘reactive’ (N=236). A selection of four biomarkers (interleukin-6, interferon gamma, angiopoietin 1/2 and plasminogen activator inhibitor-1) could be used to accurately predict the phenotype in the training cohort (area under the receiver operating characteristics curve: 0.98, 95% CI 0.97 to 0.99). Mortality rates were 15.6% and 36.4% (pConclusions Patients with ARDS can be clustered into two biological phenotypes, with different mortality rates. Four biomarkers can be used to predict the phenotype with high accuracy. The phenotypes were very similar to those found in cohorts derived from randomised controlled trials, and these results may improve patient selection for future clinical trials targeting host response in patients with ARDS.Keywords
Funding Information
- Center for Translational Molecular Medicine (MARS project.)
This publication has 39 references indexed in Scilit:
- Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndromeClinical Biochemistry, 2011
- Prognostic and Pathogenetic Value of Combining Clinical and Biochemical Indices in Patients With Acute Lung InjurySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Harmful molecular mechanisms in sepsisNature Reviews Immunology, 2008
- Nonventilatory Treatments for Acute Lung Injury and ARDSSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Comparison of Two Fluid-Management Strategies in Acute Lung InjuryThe New England Journal of Medicine, 2006
- Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress SyndromeJournal of Intensive Care Medicine, 2006
- Acute Physiology and Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today’s critically ill patients*Critical Care Medicine, 2006
- Incidence and Outcomes of Acute Lung InjuryThe New England Journal of Medicine, 2005
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2000
- ‘Unqualified Success’ and ‘Unmitigated Failure’ Number-Needed-to-Treat-Related Concepts for Assessing Treatment Efficacy in the Presence of Treatment-Induced Adverse EventsInternational Journal of Epidemiology, 1996